Expression of transcription factor FOXC2 in cervical cancer and effects of silencing on cervical cancer cell proliferation

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 4, 2014, Pages 1589-1595

  Zheng, Chun Hua ^a   Quan, Yuan ^a   Li, Yi Yang ^a   Deng, Wei Guo ^b   Shao, Wen Jing ^a   Fu, Yan ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b JILIN UNIVERSITY   (China)

Author keywords

Cervical cancer; FOXC2; Invasion; RNAi; Therapy; Tumor vessel density

Indexed keywords

CD34 ANTIGEN; CHOLECYSTOKININ OCTAPEPTIDE; FORKHEAD TRANSCRIPTION FACTOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FOXC2;

ADENOCARCINOMA; ARTICLE; BIOSYNTHESIS; CELL MOTION; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HELA CELL LINE; HUMAN; LYMPH NODE METASTASIS; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RNA INTERFERENCE; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; TUMOR INVASION; UTERINE CERVIX TUMOR;

ADENOCARCINOMA; ANTIGENS, CD34; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; RNA INTERFERENCE; RNA, SMALL INTERFERING; SINCALIDE; UTERINE CERVICAL NEOPLASMS;

EID: 84896910453     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.4.1589     Document Type: Article

References (27)

1. Dellinger MT, Thome K, Bernas MJ, Erickson RP, Witte MH (2008). Novel FOXC2 missense mutation identified in patient with lymphedema-distichiasis syndrome and review. Lymphology, 41, 98-102.
2. Forouzanfar MH, Foreman KJ, Delossantos AM, et al (2011). Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lance Oct, 1461-84.
3. Hayashi H, Kume T (2008). Foxc transcription factors directly regulate Dll4 and Hey2 expression by interacting with the VEGF-notch signaling pathways in endothelial cells.Plos One, 3, 2401.
4. Itoh M, Nakagawa H (2013). A novel complex insertion-deletion mutation in the FOXC2 gene in a Japanese patient with lymphedema-distichiasis Syndrome. Eur J Dermatol, 23, 411-13.
5. Jiang XY, Liu WK, Zhang ZX, et al (2009). According to the HPV16 E7 gene RNA interference on the biological characteristics of CaSKi cell modern. Oncology, 17, 1029-31.
6. Kreis NN, Sanhaji M, Kramer A, et al (2010). Restoration of the tumor suppressor p53 by down regulating cyclin B1 in human papilloma virus 16/18 infected cancer cells.Oncogene, 29, 5591-603.
7. Kreis NN, Sanhaji M, Kramer A, et al (2010). Restoration of the tumorsuppressor p53 by downregulating cyclin B1 in human papilloma-virus 16/18-infected cancer cells.Oncogene, 29, 5591-603.
8. Kriederman BM, Myloyde TL, Witte MH, et al (2003). FOXC2 haploinsufficient mice are a model for human autosomal dominant lymphedema-distichiasis syndrome. Hum Mol Genet, 12, 1179-85.
9. Kuhnert F, Jessica RK, Thurston G (2011). Dll4-notch signaling as a therapeutic target in tumor angiogenesis. Vascular Cell, 3, 1-8.
10. Kume T (2008). FOXC2 transcription factor: a newly described regulator of angiogenesis. Trends Cardiovasc Med, 18, 224-8.
11. Kume T (2012). The role of FOXC2 transcription factor in tumor angiogenesis. J Oncol, 2012, 204593.
12. Lee MY, Shen MR (2012). Epithelial-mesenchymal transition in cervical carcinoma.Am J Transl Res, 4, 1-13.
13. Mani SA, Yang J, Brooks M, et al (2007). Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci USA, 104, 10069-74.
14. Naohiro N, Koshi M, Takehiko Y, et al (2011). FOXC2 is a Novel Prognostic Factor in Human Esophageal SCC.Ann Surg Oncol, 18, 535-42.
15. Nishida N, Mimori K, Yokobori T, et al (2011). FOXC2 is a novel prognostic factor in human esophageal SCC. Ann Surg Oncol, 18, 535-42.
16. Petrova TV, Karpanen T, Norrmén C, et al (2004). Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasia. Nat Med, 10, 974-81.
17. Pichler A, Zelcer N, Prior JL, et al (2005). In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. Clin Cancer Res, 11, 4487-94.
18. Putral LN, Bywater MJ, Gu W, et al (2005). RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin. Mol Pharmacol, 68, 1311-9.
19. Roxanis I (2013). Occurrence and significance of epithelial-mesenchymal transition in breast cancer. J Clin Pathol, 66, 517-21.
20. Sano H, Leboeuf JP, Novitskiy SV, et al (2010). The FOXC2 transcription factor regulates tumor angiogenesis. Biochem Biophys Res Commun, 392, 201-6.
21. Sendurai A.Mani, Jing Y, Mary B, et al (2007). Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers.Proc Natl Acad Sci USA, 104, 10069-74.
22. Sima N, Wang W, Kong D, et al (2008). RNA interference against HPV16E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and P53.Apoptosis, 13, 273-81.
23. VanTrappen PO, Ryan A, Carroll M, Lecoeur C (2002). A model for coexpression pattern analysis of genes implicated in angiogenesis and tumour cell invasion in cervical cancer. Br J Cancer, 87, 537-44.
24. Vreeburg M, Heitink MV, Damstra RJ, et al (2008). Lymphedema-distichiasis syndrome: a distinct type of primary lymphedema caused by mutations in the FOXC2 gene. Int J Dermatol, 47, 52-5.
25. Wang WS, Yu SL, Yang XS, Chang SD, Hou JQ (2013). Expression and Significance of Twist and E-cadherin in Ovarian Cancer Tissues. Asian Pac J Cancer Prev, 14, 669-72.
26. Yang SH, Cheng HH, Wang ZH (2008). LYVE-1 and D2-40 in the study of early carcinoma and precancerous lesions of cervical squamous cell lymphatic microvessel in China detection. J Histochem Cytochem, 17, 588-92.
27. Yu YH, Chen HA, Chen PS, et al (2013). MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol. Oncogene, 32, 431-43.